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Abstract
Aims/hypothesis The aim of this work was to describe the clinical characteristics of adults with type 1 diabetes admitted to
hospital and the risk factors associated with severe coronavirus disease-2019 (COVID-19) in the UK.
Methods A retrospective cohort study was performed using data collected through a nationwide audit of people admitted to
hospital with diabetes and COVID-19, conducted by the Association of British Clinical Diabetologists from March to October
2020. Prespecified demographic, clinical, medication and laboratory data were collected from the electronic and paper medical
record systems of the participating hospitals by local clinicians. The primary outcome of the study, severe COVID-19, was
defined as death in hospital and/or admission to the adult intensive care unit (AICU). Logistic regression models were used to
generate age-adjusted ORs.
Results Forty UK centres submitted data. The final dataset included 196 adults whowere admitted to hospital and had both type 1
diabetes and COVID-19 on admission (male sex 55%, white 70%, with mean [SD] age 62 [19] years, BMI 28.3 [7.3] kg/m2 and
last recorded HbA1c 76 [31] mmol/mol [9.1 (5.0)%]). The prevalence of pre-existing microvascular disease and macrovascular
disease was 56% and 39%, respectively. The prevalence of diabetic ketoacidosis on admission was 29%. A total of 68 patients
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(35%) died or were admitted to AICU. The proportions of people that died were 7%, 38% and 38% of those aged <55, 55–74 and
≥75 years, respectively. BMI, serum creatinine levels and having one or more microvascular complications were positively
associated with the primary outcome after adjusting for age.
Conclusions/interpretation In people with type 1 diabetes and COVID-19 who were admitted to hospital in the UK, higher BMI,
poorer renal function and presence of microvascular complications were associated with greater risk of death and/or admission to
AICU. Risk of severe COVID-19 is reassuringly very low in people with type 1 diabetes who are under 55 years of age without
microvascular or macrovascular disease.
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Abbreviations
ABCD Association of British Clinical
Diabetologists
AICU Adult intensive care unit
COVID-19 Coronavirus disease-2019
DKA Diabetic ketoacidosis
NDA National Diabetes Audit
NHS National Health Service
NIHR National Institute for Health Research
OUH Oxford University Hospitals
NHS Foundation Trust
SARS-CoV-2 Severe acute respiratory
syndrome coronavairus-2
Introduction
The severe acute respiratory syndrome coronavirus-2 (SARS-
CoV-2) was first reported inWuhan, China in December 2019
and has since been responsible for over 1.6 million deaths
from coronavirus disease-2019 (COVID-19) infection global-
ly by December 2020 [1]. A number of studies and systematic
reviews have reported that certain chronic comorbidities, such
as hypertension, diabetes, CVD, chronic kidney disease and
chronic obstructive pulmonary disease, are associated with
increased risk of severe COVID-19 and mortality [2].
Within the population of 61 million people in England,
approximately 0.4% have type 1 diabetes and 4.7% have type
2 diabetes. An English population-based study reported that,
up to 11 May 2020, 23,698 in-hospital COVID-19-related
deaths had occurred, of which 1.5% were people with type 1
diabetes and 31.4% were people with type 2 diabetes [3]. The
study estimated that ORs for in-hospital COVID-19-related
death (adjusted for age, sex, deprivation, ethnicity and
geographical region) was 3.51 (95% CI 3.16, 3.90) for type
1 diabetes and 2.03 (1.97, 2.09) for type 2 diabetes compared
with people without diabetes [3].
Several studies have also reported the association between
admission hyperglycaemia and in-hospital mortality rate in
people with diabetes. An Italian study of 59 hospitalised
Diabetologia
patients with COVID-19 showed that those with
hyperglycaemia or diabetes had a higher mortality rate
compared with those without diabetes and euglycaemia [4].
Newly diagnosed diabetes was associated with an increased
mortality rate in a study of 453 patients admitted to hospital
with COVID-19 in Wuhan, China (HR compared with people
with normal glucose levels 9.42 [95% CI 2.18, 40.7]) [5]. A
further study of 605 COVID-19 patients admitted to two
hospitals in Wuhan showed that fasting plasma glucose
>7.0 mmol/l was independently associated with higher
28 day mortality rate after adjustment for age, sex and a
measure of COVID-19 disease severity (HR 2.30 [95% CI
1.49, 3.55]) [6]. All these studies suggest that hyperglycaemia,
including newly diagnosed diabetes, in people with COVID-
19 is associated with higher rates of complications and mortal-
ity. However, most studies have been small, from single
centres or single cities, and have not examined the complica-
tions and mortality outcomes in a specific subset of people
with diabetes. Few studies have had sufficient power to
describe factors associated with poor outcomes among people
with type 1 diabetes [7–9]. It is important to gain further
insights into the characteristics of people with type 1 diabetes
and severe COVID-19 in order to inform clinical practice and
provide accurate information to people with type 1 diabetes.
The aims of this study are to describe the characteristics of
people with type 1 diabetes admitted to hospital with COVID-
19 and to identify the risk factors associated with severe
disease.
Methods
Data collection Data for this retrospective cohort study were
collected through a nationwide audit conducted by the
Association of British Clinical Diabetologists (ABCD) [10].
A full list of ABCD Collaborators can be found in the elec-
tronic supplementary material (ESM). The nationwide audit
commenced in September 2020. Contributors were asked to
collate data from patient records and to transfer the data in
anonymous form to the National Institute for Health
Research (NIHR) Health Informatics Collaborative (HIC)
Coordinating Centre within the Oxford University Hospitals
NHS Foundation Trust (OUH). The data were transferred
securely using the National Health Service (NHS) network.
Submissions were checked by the NIHR HIC team and addi-
tional information was sought from contributing centres
where necessary to ensure completeness and accuracy. The
data were processed and analysed on a secure server within
OUH.
Ethical approval The audit was registered with the OUH and a
Data Protection Impact Assessment was carried out and
approved by the OUH Caldicott Guardian and the Public
Benefit and Privacy Panel in Scotland (reference 2021–
0111). The NHS supports audit with clear guidance for the
contributing centres on the use of routine clinical practice data
submitted in anonymised form via the secure NHS network.
As the study was retrospective, and comprised routinely
collected healthcare data only, there was no requirement for
approval by a research ethics committee.
Study variables Inpatients’ demographic information, clinical
characteristics, medication history and laboratory measure-
ments were collected from the electronic and paper medical
record systems of the participating centres by local clinicians
using a standard template. Demographic data comprised age
in years, sex, ethnicity and census-derived Index of Multiple
Deprivation decile. The following clinical characteristics were
included: weight and height, or BMI; classification of diabe-
tes; duration of diabetes; diabetes complications including
diabetic ketoacidosis (DKA), diabetic foot ulcer, diabetic
nephropathy, diabetic peripheral neuropathy, diabetic retinop-
athy, peripheral vascular disease, ischaemic heart disease
(myocardial infarction) and/or heart failure, and cerebrovas-
cular disease (stroke/transient ischaemic attack); and other
significant comorbidities (hypertension, dementia, asthma,
chronic obstructive pulmonary disease, malignant neoplasm,
smoking status). Medication history included glucose-
lowering medications and other selected drug classes (angio-
tensin-converting enzyme inhibitors or angiotensin receptor
antagonists, oral corticosteroids, statins, antiplatelet agents,
anticoagulant agents and regular nonsteroidal anti-
inflammatory drugs). Laboratory data included latest pre-
admission HbA1c and serum creatinine, and admission assays
of blood glucose, pH, bicarbonate, lactate, serum creatinine
and capillary blood ketones. Dates of the start and finish (if
applicable) of each hospital admission were collected, along
with the date of positive SARS-CoV-2 test (a positive result
was a prerequisite for inclusion in the study). Recorded
outcomes included vital status and admission to an adult inten-
sive care unit (AICU) during the entire hospital admission.
The variables relevant to the analysis of the type 1 diabetes
population were used and further data processing and analysis
is ongoing for the type 2 diabetes population. The ABCD
audit remains open and the original data collection sheet can
be obtained from the ABCD secretariat.
Statistical analysis This report is based on people with type 1
diabetes only. Baseline clinical characteristics are reported as
frequency and percentages for categorical variables, and as
mean and SD for continuous variables. The primary outcome
of the study was severe disease, defined as death or admission
to the AICU. Mortality rate alone was a secondary outcome.
Logistic regression models, with adjustment for age as a
continuous variable, were used to generate ORs for the prima-
ry outcome. For the logistic regression analysis, continuous
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variables, including BMI, admission blood glucose, latest
HbA1c and serum creatinine, were transformed into categori-
cal variables (BMI <25 [reference category], 25–29.9 and
≥30 kg/m2; admission blood glucose <10 [reference catego-
ry], 10–19.9 and ≥20 mmol/l; HbA1c < 75 [reference catego-
ry] and ≥75 mmol/mol; serum creatinine <74, 74–107 [refer-
ence category, regarded as the normal range] and >107 μmol/
l). Binary categorical variables were also created to define sex
(1 for male vs 0 for female), ethnicity (1 for non-white vs 0 for
white), DKA (1 for yes), hypertension (1 for yes), dementia (1
for yes), asthma (1 for yes), chronic obstructive pulmonary
disease (1 for yes), malignant neoplasm (1 for yes), smoking
status (1 for current/previous smoker, 0 for never smoker),
metformin use (1 for yes, 0 for no metformin), microvascular
disease (1 for having one or more conditions from diabetic
foot ulcer, diabetic nephropathy, diabetic peripheral neuropa-
thy and diabetic retinopathy) and macrovascular disease (1 for
having one or more conditions from peripheral vascular
disease, ischaemic heart disease and cerebrovascular disease).
All statistical analysis was performed using R version 3.3
(www.r-project.org/). A p value of <0.05 was considered
statistically significant.
Results
Demographic and clinical characteristics Up to 8 December
2020, a total of 40 NHS centres around the UK had submitted
data to the ABCD COVID-19 diabetes national audit. The
final dataset consisted of a total of 3312 patient records; 196
were for inpatients with type 1 diabetes who were hospitalised
between March and October 2020, of whom 194 patients had
primary outcome data submitted (discharged or died or admit-
ted to ICU). All patients were classified by the local clinical
teams as having type 1 diabetes and were confirmed to be
receiving insulin therapy.
Table 1 summarises the clinical characteristics of the whole
study population stratified by the primary outcome. There was
a slightly higher proportion of men (55%), mean (SD) age was
62 (19) years and BMI was 28.3 (7.3) kg/m2, and the majority
of people were of white ethnicity (70%). The mean (SD) latest
available HbA1c was 76 (31) mmol/mol (9.1 [5.0]%). In 80
patients (50%), the latest available HbA1c was <58 mmol/mol
(<7.5%). The prevalence of diabetic retinopathy was 45% and
of hypertension was 59%. Overall, 56% of people had a
microvascular complication (reported diabetic nephropathy,
foot ulcer, retinopathy, peripheral neuropathy) and 39% a
macrovascular complication (reported peripheral vascular
disease, ischaemic heart disease, cerebrovascular disease).
Table 2 describes the clinical outcomes in the whole type 1
diabetes population and in three different age groups. Twenty-
seven per cent of the overall population died from COVID-19
(53/194) and there was a marked age gradient, with 7%, 38%
and 38% of people aged <55, 55–74 and ≥75 years dying,
respectively. ESM Fig. 1 plots the distribution of admission
durations for those patients who died in hospital. The median
(IQR) time between admission and hospital death was 7 [4,
15] days. Most deaths (30 out of 53) occurred within 1 week
after admission but two deaths occurred after 7 weeks. A total
of 68 patients (35%) died and/or were admitted to the AICU.
Logistic regression analysis Figure 1 shows a forest plot with
ORs and 95% CIs of death and/or AICU admission for differ-
ent clinical variables after adjusting for age. ESM Table 1
reports the ORs for the primary outcome and ESM Table 2
reports the ORs for mortality rate alone. BMI, serum creati-
nine and presence of microvascular disease were positively
associated with the primary outcome after adjusting for age
while, surprisingly, higher admission blood glucose levels
were negatively associated with the primary outcome after
age adjustment. However, there was a statistically significant
difference in the mean blood glucose value between people
with DKA and those without DKA which is likely to account
for this unexpected finding. In people with DKA, the mean
(SD) admission blood glucose level was 29 (14)mmol/l, while
in people without DKA it was 15 ± 7 mmol/l (p < 0.05).
Serum creatinine and presence of macrovascular disease
were positively associated with mortality rate alone after
adjusting for age (ESM Table 2).
ESM Fig. 2 shows the distribution of eGFR, with the
majority of patients having abnormal pre-admission renal
function (eGFR <90 ml min−1 [1.73 m]−2).
Discussion
To the best of our knowledge, this study provides an analysis
of the largest cohort yet assembled of people with type 1
diabetes admitted to hospital with COVID-19 infection for
whom detailed clinical information is available. We report
distributions of age, sex, ethnicity, diabetic complications,
comorbidities, treatment on admission and laboratory test
results, stratified by outcome.
The results from the present study gives reassurance to the
younger type 1 diabetes population without diabetes compli-
cations with regards to their risk of severe COVID-19.
However, five out of 67 (7%) patients aged <55 years old
died. Of these five people, three were admitted to hospital
primarily for COVID-19 and two for DKA and all of them
had one or both of microvascular and macrovascular compli-
cations. There were no deaths in people with type 1 diabetes
under the age of 55 years old without diabetic complications.
Overall, 49 patients were admitted to hospital with DKA
(29% of 171 patients for whom data were available). This
compares with 7.3% of patients who were admitted to hospital
specifically for the management of diabetes in the 2019 UK
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National Diabetes Inpatient Audit [11]. This fourfold increase
in DKA requiring hospital admission in people with type 1
diabetes is a significant concern both for the population as
well as the healthcare system. Our findings emphasise the
importance of supporting people with type 1 diabetes in the
community during the pandemic, to minimise the incidence of
avoidable admission. Health policy development may require
population-specific attention to ethnicity as a risk factor for
DKA, because DKA incidence varied fourfold between ethnic
groups in a recently published US study [12]. We performed a
Table 1 Clinical characteristics
of the type 1 diabetes population
in the ABCD COVID-19 audit
Clinical features Available data (N=196) All Death and/or AICU
Yes No
Male sex 195 108/195 (55) 38/67 (57) 70/128 (55)
Age, years 194 62±19 65±16 56±21
Ethnicity 156
White 109/156 (70) 42/62 (68) 65/94 (69)
Asian 12/156 (8) 4/62 (6) 8/94 (9)
Black 20/156 (13) 12/62 (19) 8/94 (9)
Other 15/156 (10) 4/62 (6) 13/94 (14)
BMI, kg/m2 121 28.3±7.3 28.9±7.7 27.8±7.0
Admission blood glucose, mmol/l 122 18.6±11.3 17.3±13.5 19.6±10.2
HbA1c, mmol/mol 161 76±31 66±26 80±33
HbA1c, % 161 9.1±5.0 8.2±4.5 9.5±5.2
Creatinine, μmol/l 137 142±81 181±93 116±71
Diabetes complications
DKA on admission 171 49/171 (29) 14/64 (22) 35/107 (33)
Diabetic foot ulcer 149 32/149 (21) 12/54 (22) 20/95 (21)
Diabetic nephropathy 128 43/128 (34) 20/50 (40) 23/78 (29)
Diabetic peripheral neuropathy 140 48/140 (34) 21/55 (38) 27/85 (32)
Diabetic retinopathy 139 63/139 (45) 27/54 (50) 36/85 (42)
Microvascular diseasea 176 98/176 (56) 45/65 (69) 53/111 (48)
Macrovascular diseaseb 156 61/156 (39) 27/46 (59) 34/110 (31)
Comorbidities
Hypertension 167 98/167 (59) 40/65 (62) 58/102 (57)
Dementia 160 22/160 (14) 13/55 (24) 9/105 (9)
Asthma 150 21/150 (14) 5/61 (8) 16/89 (18)
COPD 149 17/149 (11) 7/61 (11) 10/88 (11)
Malignant neoplasm 154 15/154 (10) 5/61 (8) 10/93 (11)
Treatment on admission
Metformin 161 19/161 (12) 4/62 (6) 15/99 (15)
Insulin pump 106 9/106 (8) 1/45 (2) 8/61 (13)
Smoker 100 9/100 (9) 1/37 (3) 8/63 (13)
Data are shown as mean ± SD or n/total n (%), unless stated otherwise
aMicrovascular disease includes diabetic nephropathy, foot ulcer, retinopathy and peripheral neuropathy
bMacrovascular disease includes peripheral vascular disease, ischaemic heart disease and cerebrovascular disease
COPD, chronic obstructive pulmonary disease
Table 2 Outcomes in patients
with type 1 diabetes and COVID-
19 in different age groups
Outcome Available
data (N=196)
All age groups <55 years 55–74 years ≥75 years
Death, n/total n (%) 194 53/194 (27) 5/67 (7) 29/77 (38) 19/50 (38)
Death and/or
AICU, n/total n (%)
194 68/194 (35) 17/72 (24) 32/71 (45) 19/51 (37)
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further analysis to re-examine the association between blood
glucose levels and the primary outcome after adjusting for
both age and DKA. The results show a non-significant asso-
ciation with the primary outcome for blood glucose
≥20 mmol/l vs <10 mmol/l (OR 0.37 [95% CI 0.14, 1.03],
p = 0.06) but the association did reach statistical significance
when comparing blood glucose 10–19.9 mmol/l vs
<10 mmol/l (OR 0.35 [95% CI 0.14, 0.89], p = 0.03). We
excluded four patients who were admitted to hospital with
blood glucose <4 mmol/l in this analysis. This unexpected
finding of reduction in primary outcome (rate of death and
AICU admission) in people with modestly elevated admission
glucose compared with those with normal admission glucose
needs further confirmation from a larger dataset.
We compared the clinical characteristics of this inpatient
cohort with those of the general type 1 diabetes population
included in the retrospective registry-based population study
recently reported by the National Diabetes Audit (NDA) for
England & Wales [13]. We found similar sex and ethnicity
distribution (male, 55% vs 56%;white ethnicity, 70% vs 80%)
but our cohort was of older age and relatively poor glycaemic
control (proportion of age > 64 years, 45% vs 15%; HbA1c ≤
75 mmol/mol [9.0%], 40% vs 71%) in COVID-19 inpatients
compared with the general type 1 diabetes population. The
crude (i.e. not adjusted for age) prevalence of diabetes-
related complications was higher in COVID-19 inpatients
than in the general type 1 diabetes population as reported in
the 2017–2018 data report [14]: diabetic foot ulcer, 21% vs
5%; ischaemic heart disease, 24% vs 1.9%; cerebrovascular
disease, 15% vs 0.5%. The complications data in the NDA
report are extracted from primary care data which may be up
to 15 months old, whereas our findings are based on contem-
poraneous admission records.
To our knowledge, few studies have been published on
characteristics or outcomes in people with type 1 diabetes
and COVID-19. The largest study to date has been the
population-based study in England (population 61 million
people) describing in-hospital mortality rate among 364
people with type 1 diabetes (1.45% of all hospital admissions
due to COVID-19) [3]. The study showed that mortality was
mainly confined to an older population, with no deaths occur-
ring in those aged <50 years [3]. Another UK population
study linked data between the NDA and the Office of
National Statistics and compared the mortality rate between
the year 2020 and the three previous years [15]. The study
found that weekly death registrations in the first 19 weeks of
2020 exceeded the corresponding 3 year weekly averages for
2017–2019 by 50.9% in people with type 1 diabetes and that
the increased COVID-19-related mortality rate was associated
with cardiovascular/renal complications of diabetes and with
glycaemic control and BMI [15]. A recent Scottish population
study [16] included 51 (0.1%) of 34,383 people with type 1
diabetes who developed fatal or critical care unit-treated
COVID-19 between 1 March 2020 and 31 July 2020.
Overall, the risk of fatal or critical care unit-treated COVID-
19 was increased by 2.4 times in those with type 1 diabetes
compared with those without diabetes. Previous hospital
admissions with hypoglycaemia or DKA were strongly asso-
ciated with fatal or critical care unit-treated COVD-19.
Compared with the general population of people with type 1
diabetes, those in the fatal/AICU admission group were older
(mean age 71.4 vs 44.5 years), had higher mean BMI (27 vs
Male vs female
Non-white vs white
BMI ≥30 vs <25 kg/m2
BMI 25−29.9 vs <25 kg/m2
Blood glucose ≥20 vs <10 mmol/l 
Blood glucose 10−19.9 vs <10 mmol/l
HbA1c ≥75 vs <75 mmol/mol
Serum creatinine <74 vs 74−107 μmol/l











0.01 0.10 0.25 0.50 1.00 2.00 4.00 7.00
OR (log scale)
Fig. 1 Forest plot of the ORs (95% CIs) for the association between
severe COVID-19 (death or AICU admission) and clinical variables after
adjusting for age. The comparison groups (sample size) are: male vs
female (n = 195); non-white vs white (n = 156); BMI ≥30 kg/m2 vs
<25 kg/m2 (n = 121); BMI 25–29.9 kg/m2 vs <25 kg/m2 (n = 121); blood
glucose ≥20 mmol/l vs <10 mmol/l (n = 122); blood glucose 10–
19.9 mmol/l vs <10 mmol/l (n = 122); HbA1c ≥75 mmol/mol (≥9.0%)
vs <75 mmol/mol (<9.0%) (n = 161); serum creatinine <74 μmol/l vs 74–
107 μmol/l (n = 137); serum creatinine >107 μmol/l vs 74–107 μmol/l
(n = 137); DKA vs no DKA (n = 171); diabetic microvascular disease vs
no diabetic microvascular disease (n = 176); diabetic macrovascular
disease vs no diabetic macrovascular disease (n = 156); hypertension vs
no hypertension (n = 167); dementia vs no dementia (n = 160); asthma vs
no asthma (n = 150), chronic obstructive pulmonary disease (COPD) vs
no COPD (n = 149); malignant neoplasm vs no malignant neoplasm (n =
154); smoker vs non-smoker (n = 100); metformin vs no metformin (n =
161). The base used for logarithmic transformations on the x-axis is log10
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26 kg/m2), higher mean HbA1c (69 vs 67 mmol/mol), lower
mean eGFR (72 vs 100 ml min−1 [1.73 m]−2), higher preva-
lence of heart disease (61% vs 14%) and lower insulin pump
use (2% vs 14%). The patients included in this current study
have not been excluded from other UK-based COVID registry
studies. The present study included hospital admissions with
type 1 diabetes and COVID from 1 March until 31 October
2020.
The Coronavirus-SARS-CoV-2 and Diabetes Outcomes
(CORONADO) observational study from 68 French hospitals
reported data for 56 people with type 1 diabetes [8]. In this
cohort 55.4% were men, mean age was 56.0 years and mean
BMI of 25.8 kg/m2. At 7 days, 11 patients (19.6%) had
required tracheal intubation for mechanical ventilation, three
had died (5.4%) and nine (16.1%) had been discharged.
Overall, those with severe disease or who died were older
(65.3 vs 53.2 years) and more likely to have hypertension
(OR 5.21 [95% CI 1.24, 21.9]) than people who had not
developed these outcomes within 7 days. Poor outcomes from
COVID-19 in people with type 1 diabetes in this cohort were
most strongly related to age, with no deaths occurring in those
aged <65 years [8], whereas in a larger cohort with follow-up
until discharge and a different healthcare system, we found a
7% mortality rate in people aged <55 years. The T1D
exchange quality improvement collaborative (TIDX-QI),
involving 64 sites in the USA, reported data on 33 patients
with type 1 diabetes and laboratory-confirmed COVID-19 [7].
Among this study population, 54.5% were female and their
mean age was 24.8 years and mean HbA1c was 69 mmol/mol
(8.5%) [7]. The most prevalent comorbidities reported in this
study were obesity (39.4%) and hypertension or CVD
(12.1%). DKA occurred in 45.5% of patients [7].
Another US study conducted a retrospective chart review
in 35 people with type 1 diabetes admitted to the Beth Israel
Deaconess Medical Centre in Boston, MA, of which seven
had COVID-19 [9]. Although the cohort was small, the study
indicated that, compared with those who were COVID-19
negative, a higher proportion of SARS-CoV-2-positive
patients were of non-Hispanic Black American ethnicity, with
no significant differences in sex, body weight, glucose or
HbA1c on admission. Only one patient in the COVID-19-
positive group and two people in the COVID-19-negative
group had DKA. The study showed similar glycaemic control
prior to admission among people with type 1 diabetes, regard-
less of COVID-19 test results [9].
Our study has several strengths. The data were collected
from a large number of centres across the UK, using a struc-
tured proforma with variables prespecified based on previous
studies. This is the largest published cohort of people with
type 1 diabetes for whom contemporaneous admission data
are available. The data include ethnicity and outcomes to
discharge or death, up to 70 days from admission, reflecting
the prolonged hospital course of many patients with severe
COVID-19. Limitations to our study include the retrospective
nature of data collection and the absence of data from contem-
poraneous hospital admissions of people with type 1 diabetes
without COVID-19 infection, and from people with type 1
diabetes and COVID-19 who were not admitted to hospital.
We recognise that the patient population admitted to hospital
are significantly different from the wider type 1 diabetes popu-
lation and so the conclusions should be restricted to this
subgroup of people. A number of centres had missing data
for some of the variables (we report the completeness of vari-
ables in Table 1).
In conclusion, we report the largest study of people with
type 1 diabetes admitted to hospital with COVID-19. In this
population, higher BMI, worse renal function and the pres-
ence of microvascular complications were associated with
higher risk of death and/or admission to AICU. However, no
people with type 1 diabetes <55 years of age without micro-
vascular or macrovascular complications died or were admit-
ted to AICU.
Supplementary Information The online version contains peer-reviewed
but unedited supplementary material available at https://doi.org/10.1007/
s00125-021-05463-x.
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